Global Onychomycosis (Tinea Unguium) Drug Market Growth (Status and Outlook) 2025-2031

Global Onychomycosis (Tinea Unguium) Drug Market Growth (Status and Outlook) 2025-2031

The global Onychomycosis (Tinea Unguium) Drug market size is predicted to grow from US$ 3597 million in 2025 to US$ 5108 million in 2031; it is expected to grow at a CAGR of 6.0% from 2025 to 2031.

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.

Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.

North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.

In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.

LPI (LP Information)' newest research report, the “Onychomycosis (Tinea Unguium) Drug Industry Forecast” looks at past sales and reviews total world Onychomycosis (Tinea Unguium) Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Onychomycosis (Tinea Unguium) Drug sales for 2025 through 2031. With Onychomycosis (Tinea Unguium) Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Onychomycosis (Tinea Unguium) Drug industry.

This Insight Report provides a comprehensive analysis of the global Onychomycosis (Tinea Unguium) Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Onychomycosis (Tinea Unguium) Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Onychomycosis (Tinea Unguium) Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Onychomycosis (Tinea Unguium) Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Onychomycosis (Tinea Unguium) Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Onychomycosis (Tinea Unguium) Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:
Oral Medication
External Medicine

Segmentation by Application:
Age under 18
Age 18-50
Age above 50

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Yangtze River
Torrent Pharma
J&J
Chengdu Brilliant
Novartis
Qilu Pharmaceutical
Xiuzheng Pharmaceutical
Hubei Hengan
TARO
Perrigo
Galderma pharm
Zhejiang Deyer
Valeant Pharma
Moberg

Please note: The report will take approximately 2 business days to prepare and deliver.